Phase 3 Readout

KARD: Phase 3 Topline: A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess th

Name: Phase 3 Topline: A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess th
Start: 2028-01-01
End: 2028-01-01

January 1, 2028. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2028
Company: Kardigan, Inc. (KARD)

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess th

January 1, 2028

KARD overview →

Company: Kardigan, Inc. (KARD)
Indication: Symptomatic Genetic Dilated Cardiomyopathy